Psychedelics Wellness Company Delic: Proven Management Team with a Star-Studded Board
Ryan Allway April 9th, 2021 App, Exclusive, Psychedelics, Top News The psychedelics  sector is quickly evolving into a multi-billion-dollar industry with a growing number of publicly traded companies. As with any new industry, there are many companies backed by little more than financiers looking to make a quick dollar... Read more
Ryan Allway April 8th, 2021 Psychedelics ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada’s Section 56(1) Exemption VANCOUVER, BC, April 8, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF)... Read more
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial
Ryan Allway April 8th, 2021 Psychedelics VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to formalize discussions with the U.S. Food and... Read more
Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division
Ryan Allway April 8th, 2021 Psychedelics The Facility acquisition positions Havn Life to quickly expand its product portfolio and reach additional NHP categories. VANCOUVER, BC / ACCESSWIRE / April 8, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the... Read more
Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical
Ryan Allway April 7th, 2021 Psychedelics DENVER, April 07, 2021 — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced its four lead novel drug candidates... Read more
Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology
Ryan Allway April 7th, 2021 Psychedelics, Top News Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that... Read more
MindMed Announces the Publication of New Data on Personalized MDMA Dosing
Ryan Allway April 5th, 2021 Psychedelics BASEL, Switzerland, April 5, 2021 /CNW/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital... Read more
PsyBio Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer
Ryan Allway April 5th, 2021 Psychedelics Dr. Spigarelli’s extensive clinical and research development expertise will be integral in leading PsyBio’s development and clinical goals OXFORD, Ohio and COCONUT CREEK, Fla., April 5, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (“PsyBio“), a biotechnology company pioneering the next generation of... Read more
Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer
Ryan Allway April 1st, 2021 Psychedelics, Top News San Diego, California–(Newsfile Corp. – April 1, 2021) –  Tryp Therapeutics Inc. (CSE: TRYP) (“Tryp” or the “Company“), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has appointed Greg... Read more
NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference
Vancouver, B.C. – March 30, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FFE: 6UF) (“NeonMind”), a psychedelic drug development company, is pleased to announce that Robert Tessarolo, President & Chief Executive Officer, will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference that will be held virtually from May 4-6. He... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )